2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases
Methodological detailsinternational Task Force (22 members/15 countries), Level of evidence and grade of recommendation assigned for each recommendation; level of agreement provided anonymously by each TF member
- International Task Force (22 members/15 countries)
- Level of evidence and grade of recommendation assigned for each recommendation; level of agreement provided anonymously by each TF member
Recommendations
As issued by the authors
Infections should be discussed with patients and with other medical specialties, in accordance with national regulations (overarching principles (OAP)).
Screen for latent tuberculosis (TB) before b/tsDMARDs; screening could be considered also before csDMARDs, GC and immunosuppressants.
Interferon gamma release assay should be preferred over tuberculin skin test, where available.
HBV antiviral treatment should be guided by HBV status defined prior to starting antirheumatic drugs.
All patients positive for hepatitis-C-RNA should be referred for antiviral treatment.
Patients non-immune to varicella zoster virus should be informed about the availability of postexposure prophylaxis should they have contact with this pathogen.
Prophylaxis against Pneumocystis jirovecii seems to be beneficial in patients treated with daily doses >15-30 mg of prednisolone or equivalent for >2-4 weeks.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →